Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB

Simon Tiberi, M. C. Payen, Giovanni Sotgiu, L. D'Ambrosio, Valentina Alarcon Guizado, Jan Willem C Alffenaar, Marcos Abdo Arbex, Jose A. Caminero, Rosella Centis, Saverio De Lorenzo, Mina Gaga, Gina Gualano, Aurora Jazmín Roby Arias, Anna Scardigli, Alena Skrahina, Ivan Solovic, Giorgia Sulis, Marina Tadolini, Onno W. Akkerman, Edith Alarcon ArrascueAlena Aleska, Vera Avchinko, Eduardo Henrique Bonini, Félix Antonio Chong Marín, Lorena Collahuazo López, Gerard De Vries, Simone Dore, H. Kunst, Alberto Matteelli, Charalampos Moschos, Fabrizio Palmieri, Apostolos Papavasileiou, Antonio Spanevello, Dante Vargas Vasquez, Pietro Viggiani, Veronica White, Alimuddin Zumla, Giovanni Battista Migliori

Research output: Contribution to journalArticlepeer-review


No large study has ever evaluated the efficacy, safety and tolerability of meropenem/ clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p

Original languageEnglish
Pages (from-to)1235-1243
Number of pages9
JournalActa tuberculosea Scandinavica
Issue number4
Publication statusPublished - Apr 1 2016

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB'. Together they form a unique fingerprint.

Cite this